AU7710300A - Methods for diagnosis and therapy of hematological and virus-associated malignancies - Google Patents

Methods for diagnosis and therapy of hematological and virus-associated malignancies

Info

Publication number
AU7710300A
AU7710300A AU77103/00A AU7710300A AU7710300A AU 7710300 A AU7710300 A AU 7710300A AU 77103/00 A AU77103/00 A AU 77103/00A AU 7710300 A AU7710300 A AU 7710300A AU 7710300 A AU7710300 A AU 7710300A
Authority
AU
Australia
Prior art keywords
hematological
virus
diagnosis
therapy
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU77103/00A
Inventor
Martin A Cheever
Alexander Gaiger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AU7710300A publication Critical patent/AU7710300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU77103/00A 1999-09-22 2000-09-22 Methods for diagnosis and therapy of hematological and virus-associated malignancies Abandoned AU7710300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40444399A 1999-09-22 1999-09-22
US09404443 1999-09-22
PCT/US2000/026110 WO2001021192A2 (en) 1999-09-22 2000-09-22 Methods for diagnosis and therapy of hematological and virus-associated malignancies

Publications (1)

Publication Number Publication Date
AU7710300A true AU7710300A (en) 2001-04-24

Family

ID=23599624

Family Applications (1)

Application Number Title Priority Date Filing Date
AU77103/00A Abandoned AU7710300A (en) 1999-09-22 2000-09-22 Methods for diagnosis and therapy of hematological and virus-associated malignancies

Country Status (4)

Country Link
EP (1) EP1214595A2 (en)
AU (1) AU7710300A (en)
CA (1) CA2383615A1 (en)
WO (1) WO2001021192A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036005A2 (en) * 1999-11-15 2001-05-25 University Of Southern California Targeted delivery of therapeutic and diagnostic moieties
WO2001048205A2 (en) * 1999-12-29 2001-07-05 Corixa Corporation Murine neu sequences and methods of use therefor
PL400669A1 (en) 2000-05-19 2012-11-05 Genentech, Inc. Genetic probe for detecting a response to ErbB antagonist for improving the likelihood and efficiency of cancer treatment
WO2002013847A2 (en) * 2000-08-14 2002-02-21 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
WO2005003325A2 (en) * 2003-03-11 2005-01-13 Dana Farber Cancer Institute Inhibition of viral pathogenesis
KR20190110637A (en) 2005-01-21 2019-09-30 제넨테크, 인크. Fixed dosing of her antibodies
RU2404806C2 (en) 2005-02-23 2010-11-27 Дженентек, Инк. Extension of time to progression of disease or lifetime of oncologic patients with application of her dimerisation inhibitors
PE20090681A1 (en) 2007-03-02 2009-06-10 Genentech Inc PREDICTION OF RESPONSE TO A HER INHIBITOR
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
TW201544123A (en) 2009-03-20 2015-12-01 Genentech Inc Anti-HER antibodies
CA2761280A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CA2798837A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
CN103890007A (en) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 Neuregulin antibodies and uses thereof
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
WO2013081645A2 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
RU2014136886A (en) 2012-03-27 2016-05-20 Дженентек, Инк. DIAGNOSTIC AND TREATMENT TYPES RELATED TO HER3 INHIBITORS
MX363188B (en) 2012-11-30 2019-03-13 Hoffmann La Roche Identification of patients in need of pd-l1 inhibitor cotherapy.
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
DE69504278T2 (en) * 1994-11-10 1999-05-06 Univ Eberhard Karls Method for inhibiting the growth of leukaemic cells by HER-2 protein lines

Also Published As

Publication number Publication date
CA2383615A1 (en) 2001-03-29
WO2001021192A3 (en) 2001-08-16
EP1214595A2 (en) 2002-06-19
WO2001021192A2 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
AU2001283360A1 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
AU7710300A (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU4185100A (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
AU5788300A (en) Medical treatment method and kit
AU2002227184A1 (en) Methods for development and use of diagnostic and therapeutic agents
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002219229A1 (en) Means for the diagnosis and therapy of CTCL
AU2001220981A1 (en) Single operator exchange catheters and methods of use
AU3622600A (en) Metalloproteinases and methods of use therefor
AU715620C (en) Therapeutic methods and uses
AU4316899A (en) Method, reagent and kit for genotyping of human papillomavirus
AU2001236713A1 (en) Methods for treatment of lysosomal storage diseases
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
AU2001255521A1 (en) Biphasic reaction vessel and methods of use
AU2001273149A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001273127A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2584699A (en) Immediate early genes and methods of use therefor
AU2002319080A1 (en) Method for the diagnosis and therapy of renal cell carcinoma
AU2002218977A1 (en) Novel marker for the diagnosis and therapy of tumours

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase